Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB)

Northern Trust Corp decreased its holdings in PDS Biotechnology Co. (NASDAQ:PDSB) by 11.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,532 shares of the company’s stock after selling 10,261 shares during the period. Northern Trust Corp owned 0.22% of PDS Biotechnology worth $135,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of PDSB. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $26,000. Marshall Wace LLP boosted its position in shares of PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after acquiring an additional 10,837 shares during the period. Virtu Financial LLC bought a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $89,000. Renaissance Technologies LLC boosted its position in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after acquiring an additional 76,800 shares during the period. Finally, Blair William & Co. IL boosted its position in shares of PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after acquiring an additional 35,757 shares during the period. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Analyst Upgrades and Downgrades

PDSB has been the subject of a number of analyst reports. HC Wainwright cut their price objective on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, May 24th.

PDS Biotechnology Trading Up 8.5%

Shares of PDS Biotechnology stock opened at $1.53 on Wednesday. PDS Biotechnology Co. has a 1 year low of $0.85 and a 1 year high of $4.42. The firm has a market cap of $69.94 million, a PE ratio of -1.32 and a beta of 1.40. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The company has a 50 day simple moving average of $1.24 and a two-hundred day simple moving average of $1.49.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. Analysts expect that PDS Biotechnology Co. will post -1.2 earnings per share for the current fiscal year.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.